CSL Behring Doses First Hemophilia A Patient in Part 3 of Global Phase

King of Prussia, — CSL Behring has dosed the first patient in Part 3 of its AFFINITY clinical trial program, which is now in phase III. AFFINITY is an open-label, non-randomized, multi-center study evaluating the efficacy, safety and pharmacokinetics of its novel investigational recombinant coagulation single-chain factor VIII (rVIII-SingleChain) for the treatment of hemophilia A. […]

Talking to Your Provider About Pain

People living with a bleeding disorders know a thing or two about pain. Many with arthritis report having to wait until their body “loosens up” before they can begin their day. There’s also the pain you may feel after a particularly busy day when you’ve been on your feet, and that joint that always bothers you […]